This study was conducted at Tepecik Training and Research Hospital. Funding was provided by the Izmir Neurology Society. The first and second authors worked at Tepecik Training and Research Hospital between the years 2007 and 2009. The authors have no other funding, financial relationships, or conflicts of interest to support.
Blood levels of TNF-α, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss
Article first published online: 4 FEB 2013
Copyright © 2013 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 123, Issue 7, pages 1778–1781, July 2013
How to Cite
Demirhan, E., Eskut, N. P., Zorlu, Y., Cukurova, I., Tuna, G. and Kirkali, F. G. (2013), Blood levels of TNF-α, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss. The Laryngoscope, 123: 1778–1781. doi: 10.1002/lary.23907
- Issue published online: 24 JUN 2013
- Article first published online: 4 FEB 2013
- Manuscript Accepted: 31 OCT 2012
- hearing loss;
To investigate the blood levels of TNF-α, IL-10, and IL-12 in the idiopathic sudden sensorineural hearing loss patients, and the change of these cytokine levels after treatment.
Prospective clinical trial.
Twenty-three patients with idiopathic sudden sensorineural hearing loss and 20 healthy people were selected as study and control groups. Blood samples for TNF-α, IL-10, and IL-12 were taken before treatment and 6 weeks after treatment. The study group was given combined treatment including dexamethasone, heparin, pentoxifyline, vitamin B1, and B6 for 10 days, and was divided into two groups: treatment responders and treatment nonresponders. The treatment responders group was also divided into three groups according to most accepted criteria for improvement in the literature. Audiograms were taken before treatment and 6 weeks after treatment to determine the response to the treatment.
There was no significant difference between pre- and posttreatment values of IL-10 and IL-12 in all study groups (P > 0.05). There was also no significant difference between pre- and posttreatment values of TNF-α in treatment responders (P > 0.05). Treatment nonresponders had more elevated posttreatment values of TNF-α than pretreatment values (P < 0.05).
IL-10 and IL-12 may not play a critical role in idiopathic sudden sensorineural hearing loss. But our data supports the role of TNF-α in the pathophysiology of idiopathic sudden sensorineural hearing loss, and TNF-α receptor blockers may have benefits in these patients.
Level of Evidence
3B. Laryngoscope, 2013